Amorphis Pharma Development

What Amorphis Pharma Development does

Amorphis Pharma Development Sp. z o.o. is a Polish pharmaceutical R&D company headquartered in Katowice, Poland, specializing in the amorphization and stabilization of active pharmaceutical ingredients (APIs) to produce drugs with enhanced bioavailability and solubility. Founded in 2014 as a University of Silesia spin-off, the company was established through a partnership between academic scientists (Professor Marian Paluch and Dr Justyna Knapik-Kowalczuk), SPIN-US (the university's spin-off vehicle), HMC (pharmaceutical industry practitioners), and InnoVenture (investment fund). The company targets the Added Value Medicines segment, developing improved versions of existing generic drugs in cardiology, oncology, and immunotherapy indications.

The company's core asset is the proprietary SOLU-UP5TM stabilization method, developed by its in-house science team, which addresses the central physicochemical barrier to amorphous drug development. The technology works with BCS class II and IV compounds and is compatible with established manufacturing techniques including Hot Melt Extrusion and Spray Drying. Drugs formulated using this method reportedly demonstrate higher dissolution rates, faster absorption, equivalent therapeutic effects at lower doses, and reduced gastrointestinal side effects compared to crystalline counterparts.

Amorphis operates as a B2B development partner rather than a consumer-facing product seller. Revenue mechanics are structured around co-development agreements, milestone payments, and licensing/royalty arrangements with pharmaceutical partners. The company has received approximately 1.07 million PLN in non-dilutive funding under the EU Intelligent Development Operational Program 2014-2020 and private capital from InnoVenture. Pricing, customer identities, and revenue figures are not publicly disclosed, and the company operates solely within Poland with no documented international footprint.

Name

Amorphis Pharma Development

Legal name

Amorphis Pharma Development Sp. z o.o.

Website

https://amorphispharma.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Amorphis Pharma Development is a Polish pharmaceutical R&D company that has developed the proprietary SOLU-UP5TM technology for stabilizing amorphous active ingredients, creating improved-bioavailability generic drugs and co-developing innovative formulations with pharmaceutical partners in cardiology, oncology, and immunotherapy.

Ownership category

akta.pro rank

Product category

Pharmaceutical Drug Formulation

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industry

Solid-State Chemistry & Preformulation (Polymorph/Crystallization) (HLAGAHAI)

Keywords

• Amorphous drug formulation
• Pharmaceutical formulation
• Drug bioavailability improvement
• Pharmaceutical R&D
• Improved generic drugs

Headquarters

HQ city

Katowice

HQ country

Poland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Improved Generic Drug Development (AVM): Development and commercialization of Added Value Medicines - improved generic drugs with better bioavailability characteristics compared to original formulations. Revenue generated through development partnerships and licensing of improved formulations in selected therapeutic areas including cardiology, oncology, and immunotherapy.
2. Co-development of Innovative Formulations: Collaborative development partnerships with pharmaceutical companies to create innovative formulations containing stable amorphous substances. Revenue model based on co-development agreements, milestone payments, and potential licensing arrangements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Amorphis Pharma Development develops and licenses improved pharmaceutical formulations based on its proprietary SOLU-UP5TM method for stabilizing active substances in amorphous form. The company creates Added Value Medicines (AVM) with higher solubility, faster absorption, and equivalent therapeutic effect at lower doses, and offers co-development partnerships to pharmaceutical companies in cardiology, oncology, and immunotherapy.

Product overview

Amorphis Pharma Development is a pharmaceutical company specializing in amorphization and stabilization of active pharmaceutical ingredients. The company operates in the Added Value Medicines segment, offering the proprietary SOLU-UP5TM stabilization technology for amorphous drug development, creating improved generic drugs (AVM) in cardiology, oncology, and immunotherapy, and providing co-development services for innovative formulations with pharmaceutical partners. The company was founded by scientists from the University of Silesia in Katowice, Poland.

Differentiator

Problem solved

Functional benefit

Products and services

• SOLU-UP5TM Proprietary method for stabilizing active amorphous substances that enables creation of drugs with higher dissolution rate and absorption compared to crystalline counterparts. Applicable to BCS class II and IV compounds using Hot Melt Extrusion (HME) and Spray Drying (SD). Licensed to pharmaceutical partners.
• Improved Generic Drugs (AVM) Added Value Medicines developed by Amorphis in selected therapeutic indications including cardiology (including cholesterol), oncology, and immunotherapy. Improved versions of existing generic drugs with enhanced bioavailability through amorphous formulation, offered via licensing and development partnerships.
• Innovative Formulation Development Co-development service with pharmaceutical companies to develop innovative formulations containing stable amorphous substances, leveraging the SOLU-UP5TM stabilization method. Engagements structured as co-development agreements with milestone payments and potential licensing arrangements.

Quantifiable outcome

• Multiple improvement in drug effectiveness - smaller amorphous dose achieves same therapeutic effect as larger crystalline dose
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• SPIN-US (Uniwersytet Śląski Spin-off)coreStrategic or Co-development PartnerSpin-off company of University of Silesia providing scientific and research base support. Represents the academic foundation of the company's technology development, contributing research infrastructure and scientific expertise.
• HMC (Business Practitioners)coreStrategic or Co-development PartnerBusiness practitioners with experience in the pharmaceutical market providing industry expertise and commercial perspective for drug development activities.

Scale indicators1 record

Recent moves4 records

Expansion highlights3 records

Broad incumbents

• Hovione: Large global CDMO with established amorphous solid dispersion capabilities via spray drying and HME. Comparable on underlying technology but operates at much greater scale with a broader service portfolio.
• Aptuit (an Evotec company): Drug development services provider offering formulation and preclinical development, including enabling formulations for poorly soluble compounds — comparable in scope of formulation services.
• Catalent: Major pharma services company with extensive OptiForm amorphous formulation capabilities. Provides an established commercial path for the same BCS II/IV use cases Amorphis targets.
• Evonik (Pharma Line): Supplies pharmaceutical excipients (including polymers for amorphous solid dispersions) and CDMO services used in the same HME/spray drying processes. Adjacent incumbent with deep involvement in the value chain Amorphis serves.
• Roquette: Global excipient and CDMO player with proprietary polymer platforms (e.g., KLEPTOSE cyclodextrins) for bioavailability enhancement. Competes indirectly via enabling chemistries for amorphous formulations.

Direct peers

• Bend Research (Lonza): Pioneer in amorphous solid dispersion and bioavailability enhancement, now part of Lonza. One of the most established specialists in the exact formulation niche Amorphis targets.
• Quotient Sciences: Pharmaceutical services company offering formulation development including amorphous solid dispersions and real-time adaptive manufacturing for poorly soluble drugs — directly comparable formulation development offering.
• Ascendia Pharmaceuticals: Specialty CDMO focused on amorphous formulations and nano-emulsions for poorly soluble drugs using HME and spray drying — direct overlap with Amorphis's SOLU-UP5TM platform and target BCS II/IV compounds.

Regional players

• Polpharma Biologics: Polish pharmaceutical company with generics and biologics operations. Provides a regional reference point for a Poland-based pharma development company pursuing improved generics.
• Selvita: Polish CRO with drug discovery and formulation support capabilities. Comparable as a Poland-based life sciences services company addressing pharma R&D needs, though broader in scope than amorphous formulation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/amorphis-pharma-development

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amorphis Pharma Development